This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
catalog :
156-B7
quantity :
1 mg
price :
2360 USD
citations: 14
Reference
Cembrola B, Ruzza V, Troise F, Esposito M, Sasso E, Cafaro V, et al. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Biomed Res Int. 2019;2019:6051870 pubmed publisher
Carpenter K, Valfort A, Steinauer N, Chatterjee A, Abuirqeba S, Majidi S, et al. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer. Sci Rep. 2019;9:19530 pubmed publisher
Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10:4355 pubmed publisher
Fierle J, Abram Saliba J, Brioschi M, deTiani M, Coukos G, Dunn S. Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery. Sci Rep. 2019;9:12815 pubmed publisher
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3: pubmed publisher
Vogl U, Ohler L, Rasic M, Frischer J, Modak M, Stockl J. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy. Anticancer Res. 2017;37:1947-1955 pubmed
Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, et al. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. Mol Cancer Ther. 2017;16:861-870 pubmed publisher
Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
Liu X, Wu X, Cao S, Harrington S, Yin P, Mansfield A, et al. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. Sci Rep. 2016;6:36722 pubmed publisher
Li J, Jie H, Lei Y, Gildener Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-518 pubmed publisher
Melendreras S, Martínez Camblor P, Menéndez A, Bravo Mendoza C, González Vidal A, Coto E, et al. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE. 2014;9:e113396 pubmed publisher
Chinnadurai R, Copland I, Patel S, Galipeau J. IDO-independent suppression of T cell effector function by IFN-?-licensed human mesenchymal stromal cells. J Immunol. 2014;192:1491-501 pubmed publisher
Steidl C, Shah S, Woolcock B, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377-81 pubmed publisher
Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177:8844-50 pubmed
product information
brand :
R&D Systems
master code :
156-B7
SKU :
156-B7-01M
product name :
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
description :
The Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
PD-L1
category :
Proteins and Enzymes
unit size :
1 mg
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS and NaCl.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Human
observed molecular weight :
70-75 kDa, reducing conditions
theoretical molecular weight :
52 kDa (monomer)
gene symbol :
CD274
details of functionality :
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 µg/mL.
endotoxin note :
<0.01 EU per 1 µg of the protein by the LAL method.
catalog number base :
156-B7
accessionNumbers :
Q9NZQ7
applications :
Bioactivity
source :
Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein Human PD-L1 (Phe19-Thr239) Accession # Q9NZQ7 DIEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus
2020 USD :
2360
2021 USD :
2360 USD
alt names :
Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.